Levalbuterol hydrochloride

Bibliography

• BUCHHEIT KH, HOFMANN A, PFANNKUCHE HJ: In vitro and in vivo effects of SCA40 on guinea pig airways. Naunyn-Schmiedeberg's Arch. Pharmacol. (1997) 355:217–223.
   Google Scholar
• •Documentation of increased bronchodilator potency of racemic salbutamol following an immunological reaction in the airways.
   Google Scholar
• FOSTER A, CHAPMAN ID, MAZZONI L, MORLEY J: Resolu-tion of airway obstruction by reduction of airway hy-perreactivity. Br. J. Pharmacol. (1992) 106:3P.
   PubMed Web of Science ®Google Scholar
• WANG Z-L, BRAMLEY AM, MCNAMARA A, PARE PD, BATTR: Chronic fenoterol exposure increases in vivo and in vitro airway responses in guinea pigs. Am. J. Respir. Grit. Care Med. (1994) 149:960–965.
   PubMed Web of Science ®Google Scholar
• BRITTON J, HANLEY SP, GARNETT HV, HADFIELD JW, TATTERSFIELD AE: Dose related effects of salbutamol and ipratropium bromide on airway calibre and reac-tivity in subjects with asthma. Thorax (1988) 43:300–305.
   PubMed Web of Science ®Google Scholar
• JENNE JW, TASHKIN DP: Beta-adrenergic-agonists. In: Bronchial Asthma: Mechanisms and Therapeutics. Weiss EB, Segal MS, Stein M (Eds.), Little, Brown and Co., Boston, USA (1993)700–748.
   Google Scholar
• COCKCROFT DW, SYSTRUM VA: Functional antago- nism: tolerance produced by inhaled 02 agonists. Tho-rax (1996) 51:1051–1056.
   PubMed Web of Science ®Google Scholar
• •Summarises clinical studies that have detected loss of pro-tection following regular use of 13-agonists.
   Google Scholar
• HARVEY JE, TATTERSFIELD AE: Airway response to sal- butamol. Effect of regular salbutamol inhalations in normal, atopic and asthmatic subjects. Thorax (1982) 37:280–287.
   Google Scholar
• JENNE JW, AHRENS RC: Pharmacokinetics of beta-adrenergic compounds. In: Drug Therapy for Asthma: Re-search and Clinical Practice. Jenne JW, Murphy S (Eds.), Marcel Dekker, Inc., New York, USA (1987):213–258.
   Google Scholar
• SUISSA S, ERNST P, BOIVIN J-F et al: A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am. J. Respir. Grit. Care Med. (1994) 149:604–610.
   PubMed Web of Science ®Google Scholar
• WARNER JO: The beta2-agonist controversy and its rele-vance to the treatment of children. Eur. Respir. Rev. (1994) 4:21–26.
   Google Scholar
• ROBERTSON CF, RUBINFELD, BOWES G: Paediatricasthma deaths in Victoria: the mild are at risk. Pediatr. Pulmonol (1992) 13:95–100.
   PubMed Web of Science ®Google Scholar
• SANJAR S, AOKI S, KRISTERSSON A, SMITH D, MORLEY J. Antigen challenge induces pulmonary airway eosino-phil accumulation and airway hyperreactivity in sen-sitised guinea-pigs: the effect of anti-asthma drugs. Br. Pharmacol. (1990) 99:679–686.
   Google Scholar
• MAZZONI L, NAEF R, CHAPMAN ID, MORLEY J: Hyperre-sponsiveness of the airways to histamine following exposure of guinea-pigs to racemic mixtures and dis-tomers of beta2-selective 13 agonists. Pulm. Pharmacol (1994) 7:367–376.
   PubMedGoogle Scholar
• ••Describes induction of lethal allergic reactions by racemicsalbutamol and development of hyperresponsiveness in re-action to (S)-salbutamol.
   Google Scholar
• BARNES PJ: Beta-adrenergic receptors and their regula-tion. Am. J. Respir. Crit. Care Med. (1995) 152:838–860.
   PubMed Web of Science ®Google Scholar
• BUCHHEIT KH, HOFMANN A, FOZARD JR: Salbutamol-induced airway hyperreactivity in guinea-pigs is not due to receptor desensitisation. Eur. J. Pharmacol (1995) 287:85–88.
   PubMed Web of Science ®Google Scholar
• •Demonstrates hyperresponsiveness due to racemic salbuta-mol in the absence of desensitisation.
   Google Scholar
• MALLOLEPSZY J, KRASNOWSKA M, PASSOWICZ-MUSZYNSKA E: Bronchial reactivity after regular inha-lation of salbutamol. Pneumonol. Allergol. Pol. (1995) 63:192–196.
   PubMedGoogle Scholar
• HOSHIKO K, MORLEY J: Exacerbation of airway hyper- reactivity by racemic salbutamol in sensitised guinea-pigs. Jpn. J. Pharmacol (1993) 63:159–163.
   PubMedGoogle Scholar
• ••Demonstrates heterogeneity of hyperresponsiveness anddefines the changes in pulmonary function that underlie conversion of a mild allergic reaction to lethality following exposure to racemic salbutamol.
   Google Scholar
• JAFARIAN A, HANDLEY DA, BIGGS DF: Effects of (R,S) al- buterol on the development of antigen-mediated airway hyperreactivity in guinea pigs. Clin. Rev. Al-lergy Immunol. (1996) 14:91–100.
   Google Scholar
• BHAGAT R, SWYSTUN VA, COCKCROFT DW: Salbutamol-induced increased airway responsiveness to allergen and reduced protection vs. methacholine: dose-response. J. Allergy Clin. Immunol. (1996) 97:47–52.
   PubMed Web of Science ®Google Scholar
• CROWTHER SD, MORLEY J, COSTELLO JF: Varied effectsof regular salbutamol on airway responsiveness to in-haled spasmogens. Lancet (1997) 350:1450.
   PubMed Web of Science ®Google Scholar
• •Demonstrates heterogeneity of hyperresponsiveness due to racemic salbutamol.
   Google Scholar
• SEARS MR: Dose reduction of beta-agonists in asthma. Lancet (1991) ii:1331–1332.
   Google Scholar
• NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NA-TIONAL INSTITUTE OF HEALTH: International Consen-sus Report on Diagnosis and Management of Asthma. Eur. Respir. (1992) 5:601–641.
   PubMed Web of Science ®Google Scholar
• HANDLEY DA, MCCULLOUGH JR, CROWTHER SD, MOR-LEY J: 3 agonists enantiomers and asthma. Chirality (1998) 10:262–272.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the role of chirality in anomalous responses to f3 agonists.
   Google Scholar
• SANJAR S, KRISTERSSON A, MAZZONI L, MORLEY J, SCHAEUBLIN E: Increased airway reactivity in the guinea pig follows exposure to intravenous isoprena-line. J. Physiol. (1990) 425:43–54.
   PubMed Web of Science ®Google Scholar
• ••Analysis of the development of hyperresponsiveness in re-sponse to isoprenaline.
   Google Scholar
• AZIZ I, TAN KS, DELVIN MM, LIPWORTH BJ. Subsensitiv-ity to bronchoprotection against adenosine mono-phosphate (AMP) challenge following regular once daily formoterol. Br. J. Clin. Pharmacol (1998) 45:200P.
   Google Scholar
• CHEUNG D, TIMMERS MC, ZWINDERMAN AH et al.: Long-term effects of a long-acting beta2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. New Engl. J. Med. (1992) 327:1198–1203.
   PubMed Web of Science ®Google Scholar
• GOLDMAN P: Salmeterol and its isomers. New Engl. J. Med. (In Press.)
   Google Scholar
• NALINE E, ZHANG Y, QIAN Y et al.: Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur. Respir. J. (1994) 7:914–920.
   PubMed Web of Science ®Google Scholar
• BUCHHEIT KH, HOFMANN A: KATp channel openers re-verse immune complex-induced airways hyperreac-tivity independently of smooth muscle relaxation. Naunyn-Schmiedeberg's Arch. Pharmacol. (1996) 354:355–361.
   Google Scholar
• MORLEY J, CHAPMAN ID, MAZZONI L: SDZ MKS 492. Agents Actions (1991) 34:403–410.
   PubMedGoogle Scholar
• CHAPMAN ID, KRISTERSSON A, MATHELIN G et al.: Ef-fects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br. J. Phar-macol. (1992) 106:423–429.
   PubMed Web of Science ®Google Scholar
• BARDIN PG, DORWARD MA, LAMPE FC, FRANKE B, HOL-GATE ST: Effect of selective phosphodiesterase 3 inhi-bition on the early and late asthmatic responses to inhaled allergen. Br. J. Clin. Pharmacol. (1998) 45:387–391.
   PubMed Web of Science ®Google Scholar
• FAURSCHOU P, MIKKELSEN KL, STEFFENSEN I, FRANKE B: The lack of bronchodilator effect and short-term safety of cumulative single doses of an inhaled potas-sium channel opener (bimakalim) in adult patients with mild to moderate bronchial asthma. Pulm. Phar-macol. (1994) 7:293–297.
   PubMedGoogle Scholar
• GIEMBYCZ MA: Could selective cyclonuclotide phos-phodiesterase inhibitors render bronchodilator ther-apy redundant in the treatment of bronchial asthma? Biochem. Pharmacol. (1992) 43:2041–2051.
   Google Scholar
• ENGELS P, FICHTEL K, LUBBERT H: Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. (1994) 350:291–295.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, UNDEM RJ: Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax (1991) 46:512–523.
   PubMed Web of Science ®Google Scholar
• HARBINSON PL, MACLEOD D, HAWKSWORTH R et al.:The effect of a novel orally active selective PDE4 isoen-zyme inhibitor (CDP840) on allergen-induced re-sponses in asthmatic subjects. Eur. Respir. J. (1997) 10:1008–1014.
   PubMed Web of Science ®Google Scholar
• HAZELMANN A, ENGELSTAETTER R, MORLEY J, MAZZONI L: Enzymatic and functional inhibition of dual-selective phosphodiesterase III/IV inhibitors. In: Phos-phodiesterase Inhibitors. Schudt C, Dent G, Rabe KF (Eds.), Academic Press, London (1996).
   Google Scholar
• MURDOCH RD, COWLEY H, UPWARD J, WEBBER D, WYLD P: The safety and tolerability of Ariflo (SB 207499), a novel and selective phosphodiesterase 4 in-hibitor, in healthy male volunteers. Am. J. Respir. Grit. Care Med. (1998) 157:409A.
   Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DMet SB207499 (Ariflo), a potent and selective second genera-tion phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. (1998) 284:420–426.
   PubMed Web of Science ®Google Scholar
• HEASLIP RJ, LOMBARDO LI GOLANKIEWICZ JM et al.: Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J. Pharmacol. Exp. Ther. (1994) 268:888–896.
   Google Scholar
• WATSON JVV, BECK R, COHAN VL, SHOWELL HJ et al.: Anti-anaphylactic and side effect activity of the PDEIV inhibitor CP-80,637 in the ferret. J. Allergy Clin. Immu-nol (1995) 95 (No.1, Part 2):A353.
   Google Scholar
• MORLEY J: Opening of potassium channels: a method for resolving airway hyperreactivity. Trends Pharma-col. Sci. (1994) 15:463–468.
   PubMed Web of Science ®Google Scholar
• WEERSINK EJM, POSTMA DS, KOETER GH et al.: Picu-meterol: dissociation of improvement in lung func-tion and reduction of airways hyperresponsiveness in asthmatics. Br. J. Clin. Pharmacol (1997) 43:169–176.
   PubMed Web of Science ®Google Scholar
• BRITTAIN RT, FARMER JB, MARSHALL RJ: Some observa-tions on the 6-adrenoceptor agonist properties of the isomers of salbutamol. Br. J. Pharmacol. (1973) 48:144–147.
   PubMed Web of Science ®Google Scholar
• SEIDEHAMEL RJ, DUNGAN KW, HICKEY TE: Specific hy- potensive and antihypertensive ocular effects of d-isoproterenol in rabbits. Am. J. Ophthalmol. (1975) 79:1018–1025.
   PubMed Web of Science ®Google Scholar
• •Description of pronounced pharmacological effects of 13 agonist distomers that are unrelated to activation of 13-adrenoceptors.
   Google Scholar
• VAN METRE T: Adverse effects of inhalation of exces-sive amounts of nebulized isoproterenol in status asth-maticus. J. Allergy Clin. Immunol. (1969) 43:101–113.
   Web of Science ®Google Scholar
• SPEIZER FE, DOLL R, HEAF P, STRANG LB: Investigation into use of drugs preceding death from asthma. Br. Med. J. (1968) 1:339–343.
   PubMed Web of Science ®Google Scholar
• CONOLLY ME, DAVIES DS, DOLLERY CT, GEORGE CF: Re-sistance to beta-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Br. J. Phar-macol. (1971) 43:389–402.
   PubMed Web of Science ®Google Scholar
• •First report of anomalous hyperresponsiveness due to race-mic salbutamol.
   Google Scholar
• BAKALE RP, WALD SA, BUTLER HT et al: Albuterol: a pharmaceutical chemistry review of (R)-, (S)-, and R(S)-albuterol. Clin. Rev. Allergy Immunol. (1996) 14:7–35.
   PubMed Web of Science ®Google Scholar
• KOTLIKOFF MI, KAMM KE: Molecular mechanisms of 6-adrenergic relaxation of airway smooth muscle. Ann. Rev. Physic]. (1996) 58:115–141.
   PubMed Web of Science ®Google Scholar
• MITRA S, UGUR M, UGUR 0 et al.: (S)-albuterol increases intracellular free calcium by muscarinic receptor acti-vation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol. Pharmacol. (1998) 53:347–354.
   Google Scholar
• ••Molecular effect of 0-salbutamol that may account forhyperresponsiveness.
   Google Scholar
• PENN RB, FRIELLE T, MCCULLOUGH JR, ABERG G, BENO-VIC JL: Comparison of R-, S-, and RS-albuterol interac-tion with human 61- and 62-adrenergic receptors. Clin. Rev. Allergy Immunol. (1996) 14:37–45.
   PubMed Web of Science ®Google Scholar
• HANDLEY DA, BENOVIC JL, ABERG G, ANDERSSON RGG: In vitro studies on isomers of b2-agonists. In: 13 Agonists Enantiomers in the Treatment of Asthma. Costello JF (Ed.), Parthenon Publishing, Carnforth, UK (1997):61–70.
   Google Scholar
• MURAKI K, BOLTON TB, IMAIZUMI Y, WATANABE M: Ef-fect of isoprenaline on Ca2+ channel current in single smooth muscle cells isolated from taenia of the guinea-pig caecum. j Physiol. (1993) 471:563–582.
   PubMed Web of Science ®Google Scholar
• MURAKI K, BOLTON TB, IMAIZUMI Y, WATANABE M: Re-ceptor for catecholamines responding to catechol which potentiates voltage-dependent calcium current in single cells from guinea-pig taenia caeci. Br. J. Phar-macol. (1994) 111:1154–1162.
   PubMed Web of Science ®Google Scholar
• ••Molecular basis for anomalous actions of 13 agonists.
   Google Scholar
• BUCKNER CK, ABEL P: Studies on the effects of enanti-omers of soterenol, trimetoquinol and salbutamol on beta adrenergic receptors of isolated guinea-pig atria and trachea. J. Pharmacol. Exp. Ther. (1974) 189:616–625.
   PubMed Web of Science ®Google Scholar
• JANSON C: Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma. Eur. Respir. J. (1991) 4:544–550.
   Google Scholar
• JOHANSSON F, RYDBERG I, ABERG G, ANDERSSON RGG:Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin. Rev. Allergy Immunol. (1996) 14:57–64.
   PubMed Web of Science ®Google Scholar
• TEMPLETON AGB, CHAPMAN ID, CHILVERS E, MORLEY J,HANDLEY DA: Effects of S-salbutamol on isolated hu-man bronchus. Pul Pharmacol. Ther. (In Press.)
   Google Scholar
• RHODEN KJ, MELDRUM LA, BARNES PJ: Inhibition of cholinergic neurotransmission in human airways by beta2-adrenoceptors. j Appl. Physiol. (1988) 65:700–705.
   PubMed Web of Science ®Google Scholar
• BAI TR, LAM R, PRASAD FYF: Effects of adrenergic ago-nists and adenosine on cholinergic neurotransmis-sion in human tracheal smooth muscle. Pulm. Pharmacol. (1989) 1:193–199.
   PubMedGoogle Scholar
• ZHANG X-Y, ZHU F-X, OLSZEWSKI MA, ROBINSON NE: Effects of enantiomers of 62-agonists on ACh release and smooth muscle contraction in the trachea. Am. J. Physiol. (1998) 274:L32–L38.
   PubMed Web of Science ®Google Scholar
• BALUK P, MCDONALD DM: The 62-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am. J. Physiol. (1994) 266:L461–L468.
   PubMed Web of Science ®Google Scholar
• ERJEFALT I, PERSSON CGA: Pharmacologic control of plasma exudation into tracheobronchial airways. Am. Rev. Respir. Dis. (1991) 143:1008–1014.
   PubMed Web of Science ®Google Scholar
• BASRAM GS, PAUL W, MORLEY J, TURNER-WARWICK M:Adrenoceptor 6-agonist inhibition of the histamine-induced cutaneous response in man. Br. J. Dermatol (1982) 107:140–142.
   PubMed Web of Science ®Google Scholar
• BUTCHERS BR, FULLERTON JR, SKIDMORE IF et al.: Acomparison of the anti-anaphylactic activities of sal-butamol and disodium-cromoglycate in the rat, the rat mast cell and in human lung tissue. Br. J. Pharmacol (1974) 67:23–32.
   Google Scholar
• GOLDIE RG, SPINA D, HENRY PJ, LULICH KM, PATERSONJW: In vitro responsiveness of human asthmatic bron-chus to carbachol, histamine, 6-adrenoceptor agonists and theophylline. Br. J. Clin. Pharmacol. (1986) 22:669–676.
   PubMed Web of Science ®Google Scholar
• MUNOZ NM, VITA AJ, NEELY SP et al.: Beta adrenergic modulation of formyl-methionone-leucine-phenylalanine stimulated secretion of eosinophil per-oxidase and leukotriene C4. J. Pharmacol. Exp. Ther. (1994) 268:1339–1343.
   Web of Science ®Google Scholar
• MANOLITSAS DN, WANG J, DEVALIA L et al.: Regular al-buterol, nedocromil sodium, and bronchial inflamma-tion in asthma. Am. J. Respir. Grit. Care Med. (1995) 151:1925–1930.
   PubMed Web of Science ®Google Scholar
• GAUVREAU GM, JORDANA M, WATSON RM, COCKCROFT DW, O'BYRNE PM: Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosi-nophils in asthmatic subjects. Am. J. Respir. Grit. Care Med. (1997) 156:1738–1745.
   PubMed Web of Science ®Google Scholar
• ••Anomalous effects of racemic salbutamol upon allergicinflammation.
   Google Scholar
• VOLCHECK GW, GLEICH GJ, KITA H: Pro- and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J. Allergy Clin. Immunol. (1998) 101:S35.
   Web of Science ®Google Scholar
• KOCH P, MCCULLOUGH JR, DEGRAW SS, RUBIN PD: Pharmacokinetics and safety of (R)-, (S)- and (R,S)-a-lbuterol following nebulization in healthy volunteers. Am. J. Respir. Grit. Care Med. (1997) 155:A279.
   PubMed Web of Science ®Google Scholar
• MORGAN DJ, PAULL JD, RICHMOND BH, WILSON-EVERED E, ZICCONE SP: Pharmacokinetics of intrave-nous and oral salbutamol and its sulphate conjugate. Br. J. Clin. Pharmacol (1986) 22:587–593.
   PubMed Web of Science ®Google Scholar
• WALLE UK, PESOLA GR, WALLE T: Stereoselective sul-phate conjugation of salbutamol in humans: compari-son of hepatic, intestinal and platelet activity. Br. J. Clin. Pharmacol. (1993) 35:413–418.
   PubMed Web of Science ®Google Scholar
• EATON EA, WALLE UK, WILSON HM, ABERG G, WALLE T: Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br. J. Clin. Pharmacol. (1996) 41:201–206.
   PubMed Web of Science ®Google Scholar
• PESOLA GR, WALLE T: Enantiomeric interaction in the sulphate conjugation of the by-agonist drug albuterol by the human liver. Res. Commun. Chem. Pathol Phar-macol. (1992) 75:125–128.
   PubMedGoogle Scholar
• BOULTON DW, FAWCETT JP: Enantioselective disposi-tion of albuterol in man following oral and intrave-nous administration. Br. J. Clin. Pharmacol. (1996) 41:35–40.
   PubMed Web of Science ®Google Scholar
• •Selective accumulation of (S)-salbutamol during exposure to racemic salbutamol.
   Google Scholar
• GUMBHIR-SHAH K, KELLERMAN DJ, DEGRAW S, KOCH P, JUSKO WJ. Pharmacokinetic-pharmacodynamic char-acteristics and safety of inhaled salbutamol enanti-omers in healthy volunteers. J. Clin. Pharmacol (In Press.)
   Google Scholar
• PERRIN-FAYOLLE M: Salbutamol in the treatment of asthma. Lancet (1995) 346:1101.
   PubMed Web of Science ®Google Scholar
• •More intense and persistent responses to (R)-salbutamol as compared with racemic salbutamol.
   Google Scholar
• COCKCROFT DW, SWYSTUN VA: Effect of single doses of (S)-salbutamol, (R)-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax (1997) 52: 845–848.
   PubMed Web of Science ®Google Scholar
• NELSON HS, EDWARDS TB, BENSCH G et al.: Improved therapeutic ratio with levalbuterol versus racemic al-buterol in patients with asthma. J. Allergy Clin. Immu-nol (In Press.)
   Google Scholar
• GAWCHIK S, NOONAN C, SACCAR M, REASNER D, DE-GRAW S: A dose-ranging trial of nebulized levalbuterol solution in asthmatic subjects 2 to 11 years of age: a double-blind, randomised, cross-over study. J. Allergy Clin. Immunol. (Submitted.)
   Google Scholar
• JENNE JW, TASHKIN DP: Beta-adrenergic agonists. In: Bronchial Asthma: Mechanisms and Therapeutics. Weiss EB, Segal MS, Stein M (Eds.), Little, Brown and Co., Boston (1993):700–748.
   Google Scholar
• LIBRETTO SE: A review of the toxicology of salbutamol (albuterol). Arch. Toxicol. (1994) 68:213–216.
   PubMed Web of Science ®Google Scholar
• VIAU C, KERN T, HANDLEY DA: Acute IV and oral toxi-cology of (S)-albuterol in rats. Presented at the ACAAI Annual Meeting. Philadelphia, PA, USA (1998).
   Google Scholar
• LIPWORTH BJ, CLARK DJ, KOCH P, ARBEENY C: Pharma-cokinetics and extrapulmonary 82-adrenoceptor activ-ity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax (1997) 52:849–852.
   PubMed Web of Science ®Google Scholar
• RAUVVS AG, GROEN K: Current regulatory (Draft) guid-ance on chiral medicinal products. Chirality (1994) 6:72–75.
   PubMed Web of Science ®Google Scholar